Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Intco Medical (英科医疗) A+H: From China No.1 to Global No. 1

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Intco Medical Technology  Lt / Equity Capital Markets

<p>In the evening of June 1st, <a href="https://www.smartkarma.com/entities/intco-medical-technology-co-ltd-a" target="_blank" data-smartkarma-citation="entities:29782:1" rel="noopener">Intco Medical Technology Co., Ltd-A (300677 CH)</a> released a pre-sell down disclosure stating that the key shareholder Frank Liu and other management plan to collectively sell 22 million shares of the company.</p>
<p>Intco is ambitious to become the world' number one glove players, but we view this event as negative catalyst for Intco's A-share price and believe it will plague its Hong Kong listing. </p>
<h2>Our previous coverage on Intco A+H</h2>
<ul>
<li><a href="https://www.smartkarma.com/insights/intco-medical-a-h-from-china-no-1-to-global-no-1" target="_blank" rel="noopener">Intco Medical (英科医疗) A+H: From China No.1 to Global No. 1</a></li>
</ul>

In the evening of June 1st, Intco Medical Technology Co., Ltd-A (300677 CH) released a pre-sell down disclosure stating that the key shareholder Frank Liu and other management plan to collectively sell 22 million shares of the company.
Intco is ambitious to become the world' number one glove players, but we view this event as negative catalyst for Intco's A-share price and believe it will plague its Hong Kong listing. 
Our previous coverage on Intco A+H

Intco Medical (英科医疗) A+H: From China No.1 to Global No. 1


Intco Medical (英科医疗) A+H: A-Share Sell-Down a Red Flag